SB 786: Prescription drug pricing.
- Session Year: 2023-2024
- House: Senate
Current Status:
Passed
(2023-10-07: Chaptered by Secretary of State. Chapter 414, Statutes of 2023.)
Introduced
First Committee Review
First Chamber
Second Committee Review
Second Chamber
Enacted
Existing federal law requires the United States Secretary of Health and Human Services to enter into an agreement with each manufacturer of covered outpatient drugs to ensure the amount a covered entity is required to pay for those drugs does not exceed the average manufacturer price of the drug under the federal Medicaid program. Existing state law requires a covered entity to dispense only drugs subject to these federal pricing requirements to Medi-Cal beneficiaries. Existing law defines a covered entity to include a federally qualified health center and entities receiving specified grants and federal funding.
This bill would prohibit a pharmacy benefit manager from discriminating against a covered entity or its pharmacy in connection with dispensing a drug subject to federal pricing requirements or preventing a covered entity from retaining the benefit of discounted pricing for those drugs.
Discussed in Hearing